Trial Profile
A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Sponsors Amgen
- 06 Dec 2016 Results of long-term follow-up (five-year) resented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 05 Apr 2016 Status changed from discontinued to completed.
- 08 Dec 2015 Results of updated long-term follow-up were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.